stockrowWest Pharmaceutical Services, Inc.
WST Healthcare Medical Instruments & Supplies
West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.
- Revenue
- +8.69%
- EPS
- +56.7%
- Free cash flow
- +12.3%
- Total debt
- +0.10%
Quarter to September 2026, against a year earlier
Follow WST
Alert me
West Pharmaceutical Services, Inc. (WST) EPS (diluted)
West Pharmaceutical Services, Inc.'s EPS (diluted) for fiscal 2025 was $6.79, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $8.91. Over the past ten years it has ranged from $1.30 (fiscal 2015) to $8.67 (fiscal 2021); the current reading is higher than 73% of that period. West Pharmaceutical Services, Inc. ranks 2nd of 47 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $6.79 | 1.49% |
| FY2024 | $6.69 | (15.10%) |
| FY2023 | $7.88 | 1.94% |
| FY2022 | $7.73 | (10.84%) |
| FY2021 | $8.67 | 89.72% |
| FY2020 | $4.57 | 42.37% |
| FY2019 | $3.21 | 17.15% |
| FY2018 | $2.74 | 37.69% |
| FY2017 | $1.99 | 4.19% |
| FY2016 | $1.91 | 46.92% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $3.02 | 40.59% |
| Jun 2026 | $2.15 | 11.98% |
| Mar 2026 | $1.92 | 5.49% |
| Dec 2025 | $1.82 | (5.21%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| RMD ResMed Inc. compare | $10.98 |
| WST West Pharmaceutical Services, Inc. | $8.91 |
| ALGN Align Technology, Inc. compare | $6.87 |
| BDX Becton, Dickinson and Company compare | $3.32 |
| COO The Cooper Companies, Inc. compare | $2.93 |
| ALC Alcon compare | $1.31 |
| SOLV Solventum Corporation compare | $0.89 |
| MDLN Medline Inc. compare | $0.68 |
| BAX Baxter International Inc. compare | −$1.41 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on WST
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement